<?xml version="1.0" encoding="UTF-8"?>
<p>Studies in non-human primates have shown the prophylactic and therapeutic value of the drug in the MERS-CoV infection [
 <xref rid="B19-pharmaceuticals-13-00096" ref-type="bibr">19</xref>]. Another recent in-vitro study reported a half-maximal effective concentration (EC
 <sub>50</sub>) that suggested the drug is likely to have a plausible working concentration in non-human primates. The investigators concluded that among several drugs tested, only remdesivir (and chloroquine) could inhibit the virus infection in human cells sensitive to SARS-CoV-2 [
 <xref rid="B20-pharmaceuticals-13-00096" ref-type="bibr">20</xref>].
</p>
